Immediate Impact
51 standout
Citing Papers
Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines
2022 Standout
Potential factors influencing COVID-19 vaccine acceptance and hesitancy: A systematic review
2022 Standout
Works of Geoffrey Evans being referenced
The National Vaccine Injury Compensation Program
2011
Risky Business: Challenges in Vaccine Risk Communication
1998
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Geoffrey Evans | 245 | 72 | 18 | 184 | 124 | 19 | 595 | |
| Molly Sauer | 204 | 26 | 4 | 250 | 81 | 26 | 621 | |
| Yoko Ibuka | 176 | 18 | 5 | 178 | 190 | 28 | 671 | |
| Inayat Ali | 181 | 53 | 15 | 82 | 34 | 38 | 540 | |
| Susan K. Walker | 132 | 35 | 3 | 156 | 188 | 31 | 609 | |
| Mark C. Navin | 436 | 131 | 1 | 138 | 101 | 59 | 667 | |
| Liam Wright | 149 | 23 | 95 | 42 | 33 | 614 | ||
| Gilles Bibeau | 130 | 110 | 164 | 63 | 70 | 578 | ||
| David Scales | 95 | 28 | 10 | 115 | 95 | 43 | 685 | |
| Robert A. Rubinstein | 62 | 24 | 4 | 256 | 68 | 56 | 690 | |
| Thomas May | 47 | 62 | 9 | 90 | 98 | 50 | 616 |
All Works
Login with ORCID to disown or claim papers
Loading papers...